Abstract:The effects of the second‐generation antipsychotic risperidone (RIS) on reactive oxygen species (ROS) and microglia were analyzed using a mouse ketamine (KET) model of schizophrenia. Compared to KET‐treated mice, KET/RIS‐treated mice exhibited lower gene expression of the ROS‐generating enzyme (Nox2), and higher expression of antioxidant enzymes (Ho‐1 and Gclc). Three types of microglia were defined by hierarchical cluster analysis: resting‐ramified (type I) in control mice, moderately ramified (type II) in KET‐treated mice, and hyper‐ramified (type III) in KET/RIS‐treated mice. In vitro ROS assay showed that RIS reduced the production of microglial ROS induced by KET. Notably, antioxidant compounds (N‐Acetyl‐L‐cysteine [NAC] and GSK 2795039 [GSK]) alleviated schizophrenia‐like behaviors induced by KET, suggesting a promising direction for the development of novel treatments for schizophrenia. Recent studies have highlighted the potential involvement of reactive oxygen species (ROS) and microglia, a major source of ROS, in the pathophysiology of schizophrenia. In our study, we explored how the second‐generation antipsychotic risperidone (RIS) affects ROS regulation and microglial activation in the hippocampus using a mouse ketamine (KET) model of schizophrenia. KET administration resulted in schizophrenia‐like behaviors in male C57BL/6J mice, such as impaired prepulse inhibition (PPI) of the acoustic startle response and hyper‐locomotion. These behaviors were mitigated by RIS. We found that the gene expression level of an enzyme responsible for ROS production (Nox2), which is primarily associated with activated microglia, was lower in KET/RIS‐treated mice than in KET‐treated mice. Conversely, the levels of antioxidant enzymes (Ho‐1 and Gclc) were higher in KET/RIS‐treated mice. The microglial density in the hippocampus was increased in KET‐treated mice, which was counteracted by RIS. Hierarchical cluster analysis revealed three morphological subtypes of microglia. In control mice, most microglia were resting‐ramified (type I, 89.7%). KET administration shifted the microglial composition to moderately ramified (type II, 44.4%) and hyper‐ramified (type III, 25.0%). In KET/RIS‐treated mice, type II decreased to 32.0%, while type III increased to 34.0%. An in vitro ROS assay showed that KET increased ROS production in dissociated hippocampal microglia, and this effect was mitigated by RIS. Furthermore, we discovered that a NOX2 inhibitor could counteract KET‐induced behavioral deficits. These findings suggest that pharmacological inhibition of ROS production by RIS may play a crucial role in ameliorating schizophrenia‐related symptoms. Moreover, modulating microglial activation to regulate ROS production has emerged as a novel avenue for developing innovative treatments for schizophrenia.

Repeated Sub-anaesthetic dose of Ketamine Elevates Superoxide Dismutase in Pharmacological Model of Schizophrenia-Like Phenotypes in Mice

Lipopolysaccharide Exacerbates Ketamine-Induced Psychotic-Like Behavior, Oxidative Stress, and Neuroinflammation in Mice: Ameliorative Effect of Diosmin

[Behavior Study of Ketamine-Induced Symptoms Similar to Schizophrenia in Mice].

Combined Low Dose of Ketamine and Social Isolation: A Possible Model of Induced Chronic Schizophrenia-Like Symptoms

Effects of combined postweaning social isolation and ketamine administration on schizophrenia-like behaviour in male Sprague Dawley rats

Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice.

Ketamine Protects Against Pilocarpine-Induced Oxidative Stress and Metabolic Enzyme Disturbances During Epileptogenesis in the Epilepsy Model

Behavioral sensitization and tolerance induced by repeated treatment with ketamine enantiomers in male Wistar rats

Molecular mechanisms involved in the prevention and reversal of ketamine-induced schizophrenia-like behavior by rutin: the role of glutamic acid decarboxylase isoform-67, cholinergic, Nox-2-oxidative stress pathways in mice

Prevention and reversal of ketamine-induced experimental psychosis in mice by the neuroactive flavonoid, hesperidin: The role of oxidative and cholinergic mechanisms

Effective Action of Silymarin against Ketamine-induced Schizophrenia in Male Mice: Insight into the Biochemical and Molecular Mechanisms of Action

Sex difference alters the behavioral and cognitive performance in a rat model of schizophrenia induced by sub-chronic ketamine

The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice

Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction

Inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia

Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor Sb216763, in the Chronic Mild Stress Model of Mice

Effect of MK-801 and Ketamine on Hydroxyl Radical Generation in the Posterior Cingulate and Retrosplenial Cortex of Free-Moving Mice, As Determined by in Vivo Microdialysis

Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice

Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

L-Carnitine Prevents Behavioural Alterations in Ketamine-Induced Schizophrenia in Mice: Possible Involvement of Oxidative Stress and Inflammation Pathways